BEIJING (Reuters): A coronavirus vaccine candidate developed by the Chinese Academy of Sciences (CAS) was found to be safe and triggered immune responses in early and mid-stage trials, researchers said on Tuesday (Dec 22).
A late-stage trial of the ZF2001 vaccine, which CAS is developing with a unit of Chongqing Zhifei Biological Products, began last month in China. It aims to recruit 29,000 people across China, Uzbekistan, Indonesia, Pakistan and Ecuador.
Already a subscriber? Log in
Play, subscribe and stand a chance to win prizes worth over RM39,000! T&C applies.
Cancel anytime. Ad-free. Unlimited access with perks.
